PROMETA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prometa, and when can generic versions of Prometa launch?
Prometa is a drug marketed by Muro and is included in two NDAs.
The generic ingredient in PROMETA is metaproterenol sulfate. There are six drug master file entries for this compound. Additional details are available on the metaproterenol sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Prometa
A generic version of PROMETA was approved as metaproterenol sulfate by CHARTWELL on July 22nd, 1992.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PROMETA?
- What are the global sales for PROMETA?
- What is Average Wholesale Price for PROMETA?
Summary for PROMETA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 39 |
| Clinical Trials: | 3 |
| Patent Applications: | 3,791 |
| DailyMed Link: | PROMETA at DailyMed |
Recent Clinical Trials for PROMETA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Institute of Addiction Medicine | N/A |
| University of California, Los Angeles | Phase 2/Phase 3 |
| Medical University of South Carolina | Phase 2/Phase 3 |
US Patents and Regulatory Information for PROMETA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Muro | PROMETA | metaproterenol sulfate | SOLUTION;INHALATION | 073340-001 | Mar 30, 1992 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Muro | PROMETA | metaproterenol sulfate | SYRUP;ORAL | 072023-001 | Sep 15, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
